LIPUM AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.6 SEK | -1.15% |
|
+7.50% | +31.90% |
| 18/06 | Lipum AB Completes Multiple Dose Part of the Phase I Clinical Study | CI |
| 28/05 | Lipum AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2021 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Capitalization 1 | 93.47 | 182.4 | 182.4 | - |
| Enterprise Value (EV) 1 | 93.47 | 60.73 | 128.1 | 182.4 |
| P/E ratio | -1.48 x | - | - | - |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | - | - | - |
| EV / Revenue | - | - | - | - |
| EV / EBITDA | - | -1.63 x | -4.45 x | -3.97 x |
| EV / FCF | - | - | -48,00,708 x | -39,65,804 x |
| FCF Yield | - | - | -0% | -0% |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 5,052 | 21,212 | 21,212 | - |
| Reference price 2 | 18.50 | 8.600 | 8.600 | 8.600 |
| Announcement Date | 25/03/22 | 29/02/24 | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net sales | - | - | - | - | - |
| EBITDA 1 | - | - | -37.21 | -41 | -46 |
| EBIT 1 | - | -37.92 | -37.25 | -41 | -46 |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | - | -37.18 | -41 | -46 |
| Net income 1 | -52.26 | -38.08 | -37.18 | -41 | -46 |
| Net margin | - | - | - | - | - |
| EPS | -12.54 | - | - | - | - |
| Free Cash Flow | - | - | - | -38 | -46 |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 25/03/22 | 24/03/23 | 29/02/24 | - | - |
1SEK in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | 54.3 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | - | - | - | -38 | -46 |
| ROE (net income / shareholders' equity) | - | - | - | -1,720% | -1,859% |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 25/03/22 | 24/03/23 | 29/02/24 | - | - |
1SEK in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +31.90% | 1.76Cr | |
| +2.46% | 9.4TCr | |
| -3.42% | 3.77TCr | |
| -13.75% | 3.3TCr | |
| +73.19% | 2.83TCr | |
| -11.88% | 1.62TCr | |
| +0.49% | 1.43TCr | |
| -12.95% | 1.14TCr | |
| +190.36% | 1.1TCr | |
| -54.07% | 925.7Cr |
- Stock Market
- Equities
- LIPUM Stock
- Financials Lipum AB
